Anti Latency-Associated Peptide (LAP) Plasma Kallikrein Degradation Fragment L59 mAb (Clone 6D6)

Catalog No:
CAC-RIK-MA-L59
$563.00

Catalog numbers beginning with "CAC" are antibodies from our exclusive Cosmo Bio Antibody Collection. Visit the CAC Antibody homepage to browse the collection list, organized by research topic.

Click here to browse a well organized list of products for Bone, Collagen, and Extracellular Matrix research.

Application: ELISA, WB 
Clonality: Monoclonal 
Purification: Ig-PG 
Reactivity: Human 

Background
TGF-β is produced as a pro-protein in which the 25 kD active TGF-β is trapped by an N-terminal pro-peptide called Latency Associated Protein (LAP). Upon receipt of certain stimuli a conformational change is induced in a latent complex to release the active TGF-β from the complex. The resultant TGF-β binds to cognate signaling receptors and exerts various physiological and pathological activities. This reaction is called TGF-β activation reaction, which is known to be induced by binding of the latent complex to cell adhesion proteins such as thrombospondin and integrins, and/or by being cleaved by the action of proteases such as serine proteases, cysteine proteases, and MMPs in an organ and context-depending manner. The RIKEN Center for Biomedical Science and Research Center for Liver Cancer Prevention and Research Unit focused on the involvement of the serine protease plasmin and plasma kallikrein in the release and activation of TGF-β and its involvement in liver diseases. They showed that plasmin and plasma kallikrein cleave, respectively, at 56Lys-57Leu and 58Arg-59Leu within the LAP portion of the latent TGF-β1 molecule. The anti-TGF-β1 LAP-degradates (LAP-D) antibodies are useful to investigate the molecular mechanism of TGF-β activation and its related diseases including liver fibrosis/cirrhosis and liver degeneration.

Applications

1. Western Blotting
2. ELISA

Source

Professor Koichi, National Institute of Advanced Industrial Science and Technology RIKEN Biomedical Science Research Center Liver Cancer Prevention Research Unit

Product Description

Package Size 100 µg
Solution Liquid, PBS (pH 7.4), 0.05% NaN3
Concentration 1 mg/mL
Purity Purified from cell culture of serum-free medium by affinity column (Protein G)
Species Monoclonal Mouse IgG1 clone # 6D6
Immunogen L59 peptide [LASPPSQGEVPGGC]
Specificity Recognizes N-terminus cut end of LAP degradates (LAP-D) L59 when latent TGF-β is digested with Plasma Kallikrein (PLK).
Storage Store below -20°C. Avoid freeze-thaw cycles.

 

References
1) LAP degradation product reflects plasma kallikrein-dependent TGF-β activation in patients with hepatic fibrosis, Hara M., Kirita A., Kondo W. et al. Springerplus. May 1; 3: 221. PMCID: PMC4033717 (2014).
2) L59 TGF-β LAP degradation products serve as a promising blood biomarker for liver fibrogenesis in mice, Hara M., Inoue I., Yamazaki Y. et al. Fibrogenesis Tissue Repair. Sep 15; 8: 17. PMCID: PMC4570586 (2015).

Documents & Links for Anti Latency-Associated Peptide (LAP) Plasma Kallikrein Degradation Fragment L59 mAb (Clone 6D6)
Datasheet cac-rik-ma-l59_anti-tgf-beta1-lap-d-l59-mab-clone-6d6_datasheet.pdf

Documents & Links for Anti Latency-Associated Peptide (LAP) Plasma Kallikrein Degradation Fragment L59 mAb (Clone 6D6)
Datasheet cac-rik-ma-l59_anti-tgf-beta1-lap-d-l59-mab-clone-6d6_datasheet.pdf